- Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.
Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.
The Pediatric infectious disease journal (2007-12-29)
Todd Hatchette, Graham A Tipples, Geoff Peters, Ahmed Alsuwaidi, Jianwei Zhou, Timothy Lloyd Mailman
PMID18162946
RESUMEN
The authors describe an acyclovir-resistant varicella zoster virus infection in a pediatric patient after hematopoietic stem cell transplant, the use of foscarnet as salvage therapy, and review the literature to clarify the pediatric experience with foscarnet in this setting. A novel thymidine kinase mutation is described, along with a new phenotypic assay for characterizing acyclovir resistance in varicella zoster virus.
MATERIALES
Referencia del producto
Marca
Descripción del producto
Aciclovir, European Pharmacopoeia (EP) Reference Standard